Earlier treatment with Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmuntherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin’s lymphoma (NHL): results with second- line therapy - Emmanouilides, C; Murray, JL; Vo, K (Blood, 2003)